Oral oncology最新文献

{"title":"Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial","authors":"Guoming Xiao ,&nbsp;Li Ning ,&nbsp;Lihui Chen ,&nbsp;Shu Zhang ,&nbsp;Yingle Chen ,&nbsp;Yanfeng Chen","doi":"10.1016/j.oraloncology.2025.107844","DOIUrl":"10.1016/j.oraloncology.2025.107844","url":null,"abstract":"<div><h3>Background</h3><div>Head and neck squamous cell carcinoma (HNSCC) significantly impairs patients’ quality of life (QoL). While neoadjuvant immuno-chemotherapy offers potential survival benefits, it is associated with substantial treatment-related toxicities, including fatigue, sleep disturbances, and functional decline. Exercise therapy has shown promise in improving QoL in other cancers, but its role in HNSCC patients receiving neoadjuvant therapy remains underexplored.</div></div><div><h3>Methods</h3><div>This single-center, open-label, randomized phase II trial enrolled 114 HNSCC patients undergoing neoadjuvant immuno-chemotherapy. Participants were randomized 1:1 to an exercise group (personalized breathing and aerobic exercise program) or a control group (routine care). Outcomes were assessed using the BFI-C, EORTC QLQ-C30, QLQ-H&amp;N35, and PSQI at baseline, after 2 cycles, and after 3 cycles of therapy.</div></div><div><h3>Results</h3><div>The exercise group demonstrated significantly lower fatigue scores (BFI) after 2 and 3 cycles compared to controls (P &lt; 0.05). Sleep quality (PSQI) improved significantly in the exercise group and worsened in the control group. The exercise group also showed better outcomes in physical functioning, fatigue and insomnia.</div></div><div><h3>Conclusion</h3><div>Exercise therapy is feasible and effective in reducing fatigue and improving sleep quality in HNSCC patients receiving neoadjuvant immuno-chemotherapy. Early integration of exercise may mitigate treatment-related symptoms and improve tolerance and overall QoL.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107844"},"PeriodicalIF":3.9,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145885901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head and neck cancer trends in Denmark: A nationwide, 40-Year data analysis","authors":"Kathrine K. Jakobsen ,&nbsp;Jacob H. Rasmussen ,&nbsp;Jacob Melchiors ,&nbsp;Tina K. Agander ,&nbsp;Christian von Buchwald ,&nbsp;Christian Grønhøj","doi":"10.1016/j.oraloncology.2025.107843","DOIUrl":"10.1016/j.oraloncology.2025.107843","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Head and neck cancers (HNCs) encompass various malignancies with variation in anatomical site, histology, and survival outcomes. This study aims to describe HNC incidence and survival trends in Denmark from 1980 to 2021.</div></div><div><h3>Patients/material and methods</h3><div>This retrospective, cohort study used data from the Danish Cancer Registry and the Central Population Register to include all HNC cases in the upper aerodigestive tract from 1980 to 2021. Incidence rates were age-adjusted and survival analyzed as relative survival rates compared to the general population. Average Annual Percent Change (AAPC) in incidence was calculated using linear regression models.</div></div><div><h3>Results</h3><div>A total of 36,626 HNC cases were included. The age-adjusted incidence rate (AAIR) increased significantly from 7.1 in 1980 to 12.5 per 100,000 in 2021. From 2015 to 2021, oropharyngeal cancer was the most common HNC. Further, oropharyngeal cancer demonstrated the highest 5-year relative survival of 70.1 % [95 % CI: 67.9–72.4]. Hypopharyngeal cancer had the lowest survival (26.8 % [95 % CI: 25.1 to 28.7]). Overall, the 5-year relative survival improved during the study period from 46.9 % [95 % CI: 44.7–49.2] in 1980–1984 to 65.2 % [95 % CI: 63.8 to 66.6] in 2015–2019.</div></div><div><h3>Interpretation</h3><div>Our study showed a continued increase in incidence for HNC alongside an improvement in survival. The survival varied notably across different tumor subsite. Continued research is essential to address these variations and improve outcomes across cancer subsites. Exploring opportunities for treatment de-escalation to mitigate the toxicity associated with current therapies is essential to optimizing long-term quality of life for survivors.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107843"},"PeriodicalIF":3.9,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145878732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, risk Factors, and quality of life in patients with head and neck lymphedema following treatment for head and neck Cancer: The HeNLy-1 study","authors":"Shivakumar Thiagarajan ,&nbsp;T Rukmangathan ,&nbsp;Drub Sharma ,&nbsp;Aniket Kakade ,&nbsp;Arun Balaji ,&nbsp;Marri Rebeka ,&nbsp;Vanita Noronha ,&nbsp;Kumar Prabhash ,&nbsp;Sarbani Ghosh-Laskar ,&nbsp;Gouri Pantvaidya","doi":"10.1016/j.oraloncology.2025.107838","DOIUrl":"10.1016/j.oraloncology.2025.107838","url":null,"abstract":"<div><h3>Background</h3><div>Patients treated for head &amp; neck cancer (HNC) are at risk of developing head and neck lymphedema (HNL) that may impact their functions and quality of life (QoL). This study aimed to assess the prevalence of HNL, its risk factors, and evaluate its impact on QoL.</div></div><div><h3>Methods</h3><div>In this observational (cross-sectional) study, we included adult HNC patients who had completed definitive treatment at least 6 months prior and who had received some part of their treatment at our institute. The external lymphedema was rated using the MD Anderson Cancer Centre (MDACC) HNL rating system, and internal lymphedema using Patterson’s scale. Health-related QoL was assessed using the University of Washington quality of life questionnaire.</div></div><div><h3>Results</h3><div>A total of 421 were enrolled, with a median duration post-treatment of 19 months. HNL was present in 190 patients (45.1 %), either internal or external lymphedema or both. Most of them had stage 1a HNL. Factors that predisposed to the development of HNL were age (&gt;47 years) [p = 0.002, 1.993(1.279–2.935)], tobacco use [p = 0.025, 1.864(1.081–3.214)], and the type of treatment received, especially those who received definitive chemoradiotherapy [p &lt; 0.001,9.750(4.063–23.395)]. Patients with HNL, especially internal lymphedema, reported significantly more QoL impairments, particularly related to swallowing, chewing, xerostomia, taste and mood.</div></div><div><h3>Conclusion</h3><div>HNL was present in 45.1% of the patients in our cohort, predominantly stage 1a. Age, tobacco use, and treatment received predisposed the patient to develop HNL. Patients with internal lymphedema particularly had swallowing-related QoL issues.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107838"},"PeriodicalIF":3.9,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145842678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety reporting in head and neck squamous cell carcinoma clinical Trials: A comparative analysis of ClinicalTrials.gov data and published research","authors":"Mahad Chaudhry ,&nbsp;Annes Elfar ,&nbsp;Kaylyn Rowsey ,&nbsp;Andrew Neel ,&nbsp;Adam Khan ,&nbsp;Ty Lutze ,&nbsp;David Wenger ,&nbsp;Matt Vassar","doi":"10.1016/j.oraloncology.2025.107840","DOIUrl":"10.1016/j.oraloncology.2025.107840","url":null,"abstract":"<div><h3>Introduction</h3><div>Head and Neck Squamous Cell Carcinoma (HNSCC) is a debilitating malignancy that requires a multimodal approach in treatment, which is associated with a considerable burden of adverse events (AE). Since the 2007 FDA Amendments Act (FDAAA 801) mandates comprehensive AE reporting on ClinicalTrials.gov, the consistency of these data with corresponding peer‑reviewed publications remains unclear. This study examines the consistency of AE reporting between ClinicalTrials.gov and peer-reviewed publications for HNSCC randomized clinical trials (RCTs) conducted post-FDAAA implementation.</div></div><div><h3>Materials and Methods</h3><div>We retrospectively analyzed AE reporting on Phase II-IV HNSCC RCTs registered on clinicaltrials.gov between September 27, 2009, and January 15, 2025. Data was extracted on participant counts and total events for serious adverse events (SAEs), other adverse events (OAEs), all-cause mortality (ACM), and treatment discontinuation. Discrepancies were defined as any mismatch in counts or reporting. Chi-square and Mann-Whitney U tests assessed differences in reporting frequencies and publication delays between trial and publication data.</div></div><div><h3>Results</h3><div>Overall, 60 trials met inclusion criteria. All 60/60 (100 %) trials reported participants affected by SAEs versus 43/60 (71.7 %) publications (p &lt; 0.05), of which 33/43 (76.7 %) showed discrepant counts. Likewise, 60/60 (100 %) trials versus 22/60 (36.7 %) publications reported participants affected by OAEs (p &lt; 0.05), with 18/22 (81.8 %) mismatches. Among 24/24 (100 %) trials completed post‑2017, ACM was reported on ClinicalTrials.gov versus 15/24 (62.5 %) publications, and 22/24 (91.7 %) of those pairs differed. Participant discontinuations due to AEs appeared in 17/60 (28.3 %) registries versus 39/60 (65.0 %) publications (p &lt; 0.05); of the 15/17 (88.2 %) with both sources reporting, 9/15 (60.0 %) had discordant counts.</div></div><div><h3>Conclusion</h3><div>Substantial inconsistencies in AE, mortality, and discontinuation reporting persist between ClinicalTrials.gov and peer‑reviewed publications of HNSCC RCTs. To uphold transparency and patient safety, enhanced technical safeguards on registry platforms and stricter journal policies, such as mandatory discrepancy checklists, are urgently needed.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107840"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145841963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European surgical guidelines: transoral robotic surgery for head and neck cancers","authors":"Jérôme R. Lechien ,&nbsp;Vinidh Paleri ,&nbsp;Robin Baudouin ,&nbsp;Aina Brunet ,&nbsp;Carlos M. Chiesa-Estomba ,&nbsp;Erika Crosetti ,&nbsp;Andrea De Vito ,&nbsp;Giovanni Cammaroto ,&nbsp;Armando De Virgilio ,&nbsp;Nicolas Fakhry ,&nbsp;Wojciech Golusinski ,&nbsp;Heikki Irjala ,&nbsp;Stefan Lang ,&nbsp;C.Rene Leemans ,&nbsp;Sylvain Moriniere ,&nbsp;Alberto M. Saibene ,&nbsp;Claudio Sampieri ,&nbsp;Somiah Siddiq ,&nbsp;Vincent Vander Poorten ,&nbsp;David Viros Porcuna ,&nbsp;Stéphane Hans","doi":"10.1016/j.oraloncology.2025.107826","DOIUrl":"10.1016/j.oraloncology.2025.107826","url":null,"abstract":"<div><h3>Background</h3><div>Substantial heterogeneity in practice exists across centers regarding the indications and perioperative care for patients undergoing transoral robotic surgery (TORS) for head and neck cancer. This consensus paper aims to propose a European surgical practice guideline in this setting.</div></div><div><h3>Methods</h3><div>Twenty-two experts from European and International scientific societies participated in a modified Delphi process for rating and validating statements about indications, contraindications, surgical outcomes, and pre- and postoperative care associated with TORS for head and neck cancer care. Consensus was deemed to have been achieved when two-thirds of experts agreed or strongly agreed with the statement; those with fewer than one-third agreement were improved and resubmitted for voting until final validation or rejection.</div></div><div><h3>Results</h3><div>Of the initial 41 statements, 38 reached consensus after three voting rounds. Statements propose recommendations for the preoperative assessment (n = 7), indications and contraindications for TORS in oropharyngeal, laryngeal, and hypopharyngeal primaries (n = 10), surgical outcomes to be reported (n = 7), postoperative care (n = 8), and clinical research (n = 6). TORS is appropriate for small, accessible oropharyngeal and supraglottic tumors with favorable exposure. The contraindications set out in detail for oropharyngeal, laryngeal and hypopharyngeal lesions will assist in decision-making, especially when presented with a controversial clinical scenario. Standardized reporting of surgical, functional, and oncological outcomes, including swallowing, voice quality, and survival rates, is essential for evidence-based practice. TORS represents a promising avenue for therapeutic de-escalation in HPV-positive oropharyngeal cancers.</div></div><div><h3>Conclusion</h3><div>The European TORS surgical consensus provides clinical recommendations for the indications, contraindications, surgical and perioperative care for TORS management of head and neck malignancies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107826"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145841964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head and neck squamous cell carcinoma following allogeneic bone marrow transplantation: Clinical features, genomic Alterations, and limited efficacy of palliative chemotherapy","authors":"Song Ee Park ,&nbsp;Sook-Hee Hong ,&nbsp;Jun-Ook Park ,&nbsp;Sang-Yeon Kim ,&nbsp;Dong-Il Sun ,&nbsp;Yeon-Sil Kim ,&nbsp;Won-Jong Park ,&nbsp;Meejeong Kim ,&nbsp;Youn Soo Lee ,&nbsp;Jin Hyoung Kang","doi":"10.1016/j.oraloncology.2025.107827","DOIUrl":"10.1016/j.oraloncology.2025.107827","url":null,"abstract":"<div><h3>Background</h3><div>Head and neck squamous cell carcinoma (HNSCC) is an uncommon but serious late complication after allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated clinical features, molecular alterations, and outcomes of post-HSCT HNSCC, with emphasis on recurrent disease.</div></div><div><h3>Methods</h3><div>Thirty-four patients diagnosed with HNSCC after allogeneic HSCT between January 2009 and May 2025 were retrospectively analyzed. Clinical characteristics, transplantation history, tumor location, HPV status, treatment, PD-L1 expression, and survival were assessed. Whole-exome sequencing (WES) was performed.</div></div><div><h3>Results</h3><div>Median age at HNSCC diagnosis was 53 years (range, 6–75), with 73.5 % male. Leukemia was the most common primary malignancy (70.5 %). The oral tongue was the most frequent site (55.9 %), followed by buccal mucosa (23.5 %). Median interval from HSCT to HNSCC was 86.8 months (95 % CI, 72.4–104.7), and median follow-up was 54.8 months (95 % CI, 24.1–85.4). Chronic GVHD was associated with inferior disease-free survival (44.4 months vs. not reached; HR 3.98; 95 % CI, 1.05–15.04; P = 0.044). Among four patients with recurrent HNSCC receiving palliative chemotherapy, median progression-free survival was only 0.7 months (95 % CI, 0.669–0.865). One patient with high PD-L1 expression received pembrolizumab but derived limited benefit. WES identified recurrent TP53 mutations and alterations in PIK3R2, KIT, EGFR, and PIK3CA. All tumors were microsatellite stable with low tumor mutational burden.</div></div><div><h3>Conclusions</h3><div>HNSCC after HSCT typically develops after prolonged latency and shows favorable outcomes with curative therapy. However, recurrence is marked by rapid progression and poor systemic treatment response, underscoring the prognostic relevance of chronic GVHD and the need for novel therapeutic strategies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107827"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145841962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma","authors":"Meng Zhang ,&nbsp;Jian Song ,&nbsp;Yiming Yuan ,&nbsp;Xiujuan Cao","doi":"10.1016/j.oraloncology.2025.107841","DOIUrl":"10.1016/j.oraloncology.2025.107841","url":null,"abstract":"<div><h3>Purpose</h3><div>To develop and validate a multimodal ensemble machine learning model integrating multi-sequence magnetic resonance imaging (MRI) radiomics, clinical characteristics, and hematological biomarkers for early prediction of Radiation-induced temporal lobe injury (RTLI) in Nasopharyngeal carcinoma (NPC) patients before radiotherapy.</div></div><div><h3>Methods</h3><div>A total of 161 NPC patients treated with intensity-modulated radiation therapy (IMRT) were retrospectively analyzed and randomly assigned to training (n = 113) and validation (n = 48) sets in a 7:3 ratio. Radiomic features were extracted from pretreatment T1WI, CE-T1WI, T2WI, and DWI, with features showing ICC &gt; 0.75 retained. After SMOTE balancing, Elastic Net (EN) was used for feature selection to generate EN-scores, and Random Forest (RF) produced RF-scores. These, together with two SVM-based scores obtained from demographic and hematological biomarkers, were combined into an ensemble ERSS (EN–RF–SVM–SVM) model. Model performance was evaluated using ROC analysis, calibration, and decision curve analysis.</div></div><div><h3>Results</h3><div>The ERSS model demonstrated superior predictive performance compared with single-sequence, multi-sequence MRI integration models and LR model. The AUCs of the ERSS model were 0.957 in the training set and 0.968 in the validation set. Calibration curves showed excellent agreement between predicted and observed outcomes. DCA indicated that the ERSS model provided the highest net clinical benefit across a wide range of threshold probabilities compared with other models.</div></div><div><h3>Conclusion</h3><div>The ERSS multimodal ensemble learning model provides a highly accurate and clinically meaningful tool for early prediction of RTLI in NPC patients. By integrating multi-sequence MRI radiomics, hematological biomarkers, and clinical factors, the ERSS model enables individualized risk assessment and may assist in optimizing radiotherapy planning and follow-up strategies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107841"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145841965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Jaw-in-a-day (JIAD) for malignant indications: A systematic review","authors":"Jessica Trac ,&nbsp;Rashi Ramchandani ,&nbsp;Pallavi Dutta ,&nbsp;Leba Sarkis ,&nbsp;Robert Calvisi ,&nbsp;Noémie Villemure-Poliquin ,&nbsp;Joel Davies ,&nbsp;Eszter Somogyi-Ganss ,&nbsp;Nick Blanas ,&nbsp;Karl Cuddy ,&nbsp;Danny Enepekides ,&nbsp;Kevin Higgins ,&nbsp;Justine Philteos ,&nbsp;Antoine Eskander","doi":"10.1016/j.oraloncology.2025.107823","DOIUrl":"10.1016/j.oraloncology.2025.107823","url":null,"abstract":"<div><h3>Introduction</h3><div>Jaw-in-a-day (JIAD) achieves resection, maxillofacial reconstruction and immediate dental rehabilitation. While increasingly used, evidence in oncologic populations remains limited. Our objective was to review JIAD in patients with head and neck cancer (HNC) and its outcomes.</div></div><div><h3>Methods</h3><div>Our systematic review was conducted following a predefined protocol (PROSPERO CRD420251043510). Our search strategy was executed on MEDLINE, Embase, CENTRAL, Web of Science, and CINAHL from January 2013 to October 2025. Studies with HNC patients of all ages who underwent JIAD were included. The Methodological Index for Non-Randomized Studies (MINORS) was used for risk of bias assessment.</div></div><div><h3>Results</h3><div>Nine studies were included with 57 patients. Common tumour characteristics included mandibular location (n = 31; 54.4 %) and squamous cell carcinoma pathology (n = 37; 64.9 %). A fibular free flap was used in all cases (n = 57; 100 %). Majority underwent adjuvant therapy (n = 36; 63.2 %). Prosthesis survival was reported in 6 studies (n = 25/32; 78.1 %) with follow-up periods ranging from 5 to 52 months. Prosthesis removal was commonly due to osteoradionecrosis (ORN) (n = 6; 10.5 %). All irradiated implants had successful early osseointegration (n = 99; 100 %). Delayed implant failure was reported in 4 patients (n = 4/36; 11.1 %) with 11 implants in radiotherapy field (n = 11/99; 11.1 %).</div></div><div><h3>Conclusion</h3><div>JIAD for HNC patients can have high success in majority of select patients/defects. Although early osseointegration rates were high, oncologic patients receiving adjuvant radiation may remain at elevated risk for ORN-associated prosthesis failure. As such, the risks and benefits of JIAD should be carefully reviewed with the patient, and cancer staging should also be considered.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107823"},"PeriodicalIF":3.9,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145799798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma","authors":"Qin Liu ,&nbsp;Jing-Ni Wei ,&nbsp;Jia-Yu Zhou ,&nbsp;Chuan-Run Zhang ,&nbsp;Liang-Ru Ke ,&nbsp;Nian Lu ,&nbsp;Ying Deng ,&nbsp;Yu-Wen Kuang ,&nbsp;Yu-Chen Hua ,&nbsp;Meng-Wen Wang ,&nbsp;Jie Gong ,&nbsp;Shu-Hui Dong ,&nbsp;Longjunyu Wu ,&nbsp;Xing Lv ,&nbsp;Yan-Qun Xiang ,&nbsp;Xiang Guo ,&nbsp;Wei-Xiong Xia","doi":"10.1016/j.oraloncology.2025.107825","DOIUrl":"10.1016/j.oraloncology.2025.107825","url":null,"abstract":"<div><h3>Purpose</h3><div>To develop a retropharyngeal lymph node (RLN)-based scoring system using anatomical features and to evaluate its utility in optimizing N classification in patients with nasopharyngeal carcinoma (NPC).</div></div><div><h3>Materials and methods</h3><div>This retrospective cohort study included patients with nonmetastatic NPC treated at two tertiary referral cancer centers in China between January 2012 and December 2018. Univariate and multivariate analyses were used to evaluate the association between MRI-based RLN features and multiple survival endpoints. A simplified RLN risk scoring (RRS) system (incorporating RLN multiplicity, MID, adENE and CNN) was developed in SYSUCC cohort and validated in the GMUCH cohort. A new N classification system was proposed and compared with the 9th edition of AJCC N staging system using C-index.</div></div><div><h3>Results</h3><div>Positive RLNs were observed in 68.3 % of all patients, including 66.7 % (690/1035) in the SYSUCC cohort and 72.0 % (340/472) in the GMUCH cohort. High RRS (defined as RRS &gt; 2) was independently associated with worse OS (hazard ratio [HR], 2.22; 95 % CI, 1.56–3.15, <em>P</em> &lt; 0.001), PFS (HR, 2.45; 95 % CI, 1.87–3.20, <em>P</em> &lt; 0.001), DMFS (HR, 2.71; 95 % CI, 1.88–3.91, <em>P</em> &lt; 0.001), and RFS (HR, 2.20; 95 % CI, 1.51–3.20, <em>P</em> &lt; 0.001). The proposed N classification system incorporated high RRS as a criterion for N3 disease, demonstrated higher C-index values compared with the 9th edition AJCC staging system for OS (0.666 vs 0.659), PFS (0.659 vs 0.639), DMFS (0.682 vs 0.663), and RFS (0.644 vs 0.629).</div></div><div><h3>Conclusions</h3><div>High RRS was strongly correlated with inferior survival outcomes in NPC patients. Integrating high RRS into the current staging system by reclassifying these patients as N3 might improve prognostic stratification and offer more precise treatment guidance.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107825"},"PeriodicalIF":3.9,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145799911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influencing factors on occurrence and prognosis of oral squamous cell carcinoma after organ transplantation","authors":"Yiheng Feng ,&nbsp;Maged Ali Al-Aroomi ,&nbsp;Jie Chen ,&nbsp;Saiwen Song ,&nbsp;Canhua Jiang ,&nbsp;Jie Wang","doi":"10.1016/j.oraloncology.2025.107824","DOIUrl":"10.1016/j.oraloncology.2025.107824","url":null,"abstract":"<div><h3>Objectives</h3><div>Patients who undergo solid organ or hematopoietic stem cell transplantation are at an increased risk of developing oral squamous cell carcinoma (OSCC) due to prolonged immunosuppression. The specific characteristics and prognostic outcomes of OSCC in these post-transplant patients are not well understood. This study aims to investigate the risk, characteristics, and prognostic outcomes of OSCC in post-transplant patients.</div></div><div><h3>Methods</h3><div>This study analyzed the clinical baseline characteristics of OSCC patients with pathological confirmation who had undergone organ transplantation (study group) and non-transplant OSCC patients (control group), all of whom were monitored with comprehensive follow-up. Survival outcomes, including overall survival (OS) and disease-free survival (DFS), were assessed using the Kaplan-Meier method. The Cox proportional hazards model was used to evaluate whether organ transplantation status was an independent risk factor affecting survival.</div></div><div><h3>Results</h3><div>A total of 103 patients were enrolled (study group, n = 17; control group, n = 86). The median age at OSCC diagnosis for study group was 53 years, with tumors primarily located on the tongue (35.3 %), buccal (17.6 %), and gingiva (11.8 %). Control group had a similar median age, with tumors mostly located on the tongue (64.0 %), buccal (16.3 %), and gingiva (8.1 %). Except for one transplant recipient who received conservative management, all patients underwent surgical resection. Cox multivariate analysis identified tumor recurrence (p = 0.002), tumor size (p = 0.016), and vascular invasion (p = 0.006) as significant adverse factors affecting survival.</div></div><div><h3>Conclusion</h3><div>This study emphasizes the importance of organ transplantation history in managing OSCC. Regular screening is essential for early detection and improved survival, particularly under immunosuppressive conditions, in this high-risk group.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107824"},"PeriodicalIF":3.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145787203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}